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 Summary 
Although in most cases von Willebrand Disease (VWD) is a mild disorder, a subgroup 
of patients experience frequent bleeding. In contrast to severe haemophilia where 
prophylaxis is the accepted standard of care, this is less frequently used in VWD. 
Most type 1 VWD patients can be adequately managed with episodic desmopressin 
and tranexamic acid. In patients with more severe disease, especially those with 
type 3 VWD, joint bleeds, epistaxis, menorrhagia and gastrointestinal bleeding are 
problematic and usually require treatment with von Willebrand Factor (VWF/FVIII) 
concentrate. Whilst in the past these patients were managed with on demand 
VWF/FVIII concentrate, several recent reports have demonstrated the value of 
prophylactic treatment. Despite some uncertainties about the economic impact of 
treatment of severe VWD, prophylaxis with VWF concentrate should now be 
considered as the standard of care for the more severe end of the spectrum of 
affected individuals. The recent introduction of recombinant VWF concentrate is 
likely to improve the acceptability of prophylaxis. 
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Introduction 
     Haemophilia and von Willebrand disease (VWD) due to deficiency of FVIII/IX and 
von Willebrand factor (VWF) respectively, comprise the most common inherited 
bleeding disorders. Despite the obvious differences in mode of inheritance and 
pathophysiology, they share a number of characteristics. As with all the inherited 
bleeding disorders, there is a direct relationship between the severity of the factor 
deficiency and the symptoms of disease and correction of the deficiency stops and 
prevents bleeding. 
     VWD is caused by abnormalities in the VWF gene on chromosome 12, with an 
autosomal dominant or recessive inheritance pattern (1). Although VWD is the most 
common inherited bleeding disorder, most diagnosed individuals have mild disease 
(2). Typical symptoms are those of mucosal bleeding including epistaxis, 
menorrhagia, as well as skin bruising and bleeding after surgery and dental 
extractions. Treatment of VWD is primarily conducted with tranexamic acid, 
desmopressin or VWF/FVIII concentrate, which are given to stop bleeding or prevent 
bleeding in the context of surgery. In contrast to the situation in haemophilia, the 
use of long-term prophylaxis is less well developed in VWD. 
     Haemophilia is inherited in a sex-linked manner and largely affects males, 
although some female carriers can have reduced levels and also be symptomatic. 
Typical symptoms are joint and muscle bleeding as well as internal bleeding, and 
bleeding after surgery and invasive procedures. There is an inverse relationship 
between residual factor level and severity of bleeding. Individuals with severe (<1% 
FVIII/IX) disease experience frequent spontaneous joint bleeds and develop 
 arthropathy whilst persons with moderate (1% to <5% FVIII/IX) disease experience 
joint bleeds less frequently and rarely develop severe arthropathy (5-6). This 
observation led to the suggestion that if you could administer regular FVIII/IX to 
always have a level above 1% then it should be possible to reduce the number of 
joint bleeds and convert the phenotype of patients with severe disease to that of 
moderate/mild individuals. 
 
Haemophilia and prophylaxis 
     A five-decade clinical experience, starting in Sweden (3-4) has established 
prophylaxis using regular infusions of factor concentrate as the treatment of choice 
in children with severe haemophilia. 
     Data supporting the benefits of prophylaxis in haemophilic patients largely come 
from retrospective or non-controlled studies. The different cohorts of patients 
described in the Malmo experience (3) and in other studies in the following years (7-
9) evaluated short-term outcome such as frequency of joint bleeds, or long-term 
clinical outcome such as arthropathy (10-11). Clinical and radiological scores 
demonstrated that signs of arthropathy were not detectable in children starting 
prophylaxis before two years of age (8), or showing that only younger children 
receiving higher doses earlier in life did not develop any bleeding episode (3). In 
some of these stƵĚŝĞƐŽƚŚĞƌŵĞĚŝĐĂůĂŶĚƐŽĐŝĂů ŝŵƉůŝĐĂƚŝŽŶƐŽŶƉĂƚŝĞŶƚƐ ?YƵĂůŝƚǇŽĨ
Life (QoL) were also investigated (e.g., number of hospital visits and hospitalisations, 
number of school/work days lost). 
     Despite the long clinical experience and extensive use of prophylaxis in this 
setting, a Cochrane review in 2006 concluded that evidence supporting clinical 
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benefits of prophylaxis over on-demand therapy was insufficient (12). In the last 
decade, however, several randomized-controlled studies (13-14) have definitively 
confirmed primary prophylaxis as the gold standard of care in severe hemophilia, 
and national guidelines in several countries now advise commencing early 
prophylaxis (15-16). 
     Current prophylaxis regimens do not completely prevent joint disease (13). In the 
last few years, more intensive prophylaxis regimens have been explored (17), 
achieving almost zero joint bleeds. To get the best outcomes with the available 
ƌĞƐŽƵƌĐĞƐ ? ŝŶĚŝǀŝĚƵĂůŝǌĂƚŝŽŶ ŽĨ ƚŚĞƌĂƉǇ ŝƐ ĂƉƉůŝĞĚ ?ǁŚŝĐŚ ĐŽŶƐŝĚĞƌƐ ƚŚĞ ŝŶĚŝǀŝĚƵĂů ?Ɛ
bleeding pattern, condition of their musculoskeletal system, level of physical activity 
and the pharmacokinetic profile of the clotting factor concentrate used (18-22). 
In order to optimize therapeutic regimens related to outcomes, several studies 
suggested starting with a once-weekly regimen (23-24). 
 
Von Willebrand Disease 
     Although VWD is more prevalent than haemophilia, less evidence is available on 
its optimal management, probably due to the lesser number of patients with severe 
disease. In the International Society on Thrombosis and Hemostasis (ISTH) 
classification, different VWD types are recognized depending on the quantitative 
(types 1 or 3) or qualitative (type 2) deficiency that includes four sub-types: 2A, 2B, 
2M and 2N (25). 
     The clinical VWD manifestations are mucocutaneous bleeding and prolonged 
oozing after surgical or invasive procedures. Menorrhagia may be the only clinical 
manifestation. Soft tissue and joint bleeds are rare, except in Type 3 VWD. The 
 severity of the bleeding tendency is usually proportional to the degree of the 
primary deficiency of VWF and to the secondary deficiency of FVIII. The expression 
of the disease is mild in most patients with type 1, and more severe in some type 2 
and particularly in type 3 VWD. Several attempts have recently been made to 
evaluate sensitivity and specificity of bleeding symptom in VWD diagnosis. A 
bleeding severity score has now been developed to aid the diagnosis of VWD (26). 
     Management of VWD includes the prevention or treatment of bleeding by 
correcting the primary haemostasic defect and the coagulation defect due to FVIII 
deficiency (27-28). Correction of both deficiencies and raising endogenous VWF 
levels can be achieved by administering the synthetic peptide desmopressin 
(deamino-8-D-arginine vasopressin; DDAVP) or, in unresponsive patients, plasma-
derived VWF/FVIII or VWF concentrates devoid of FVIII (28-31). Antifibrinolytic 
agents such as tranexamic and epsilon aminocaproic acid, platelet concentrates and 
combined estrogen-progestogen drugs can be co-administered (32). 
     Prevention of bleeding is achieved by prophylaxis, which can be performed in 
case of surgery or invasive procedures (short-term) or, in the severe forms of VWD, 
to prevent recurrent bleeding episodes (long-term prophylaxis). 
 
Short-term prophylaxis for surgery 
The choice of the best treatment regimen before surgery in patients with VWD 
depends on type of VWD, type of surgery, baseline VWF and FVIII levels, response to 
DDAVP and its potential side-effects. Table 1 show Italian guidelines for prophylaxis 
before surgery (28); substantially similar advice is given in the UK and USA 
Guidelines (33,34). 
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Desmopressin (DDAVP) is the first-choice option for patients with Type 1 VWD and 
baseline VWF and FVIII levels higher than 10 U/dL (35). Type 2 patients have a highly 
variable pattern of response to DDAVP which is better in type 2M than in Type 2A 
(36). In Type 2B, DDAVP remains controversial because of the potentially transient 
appearance or aggravation of thrombocytopenia, which could increase bleeding. 
Patients with type 3 VWD are always unresponsive to DDAVP. In type 2N VWD 
associated with homozygous or heterozygous R854Q, DDAVP is usually able to 
correct FVIII deficiency, although its half-life may be relatively short (35, 37). In 
patients with isolated collagen-binding defects, desmopressin improves all VWF/FVIII 
measurements including VWF:CBA, albeit with a persistent discrepancy of 
VWF:CBA/VWF:Ag ratio(36,38). 
     A test infusion of DDAVP (0.3 micrograms/kg) is recommended to establish the 
individual response pattern and to plan its appropriate use, because of the 
variability in response to DDAVP between patients, which reasons are not clear. 
Furthermore, patients treated repeatedly with DDAVP may become less responsive, 
probably because stores are exhausted. The average factor VIII responses obtained if 
DDAVP is repeated at 24 -hours intervals are approximately 30% less that then 
obtained after the first dose, with a consequent limitation of the use of DDAVP when 
Factor VIII levels must be maintained above the baseline levels for a prolonged 
period of time, as in major surgery. 
In VWD patients in whom DDAVP is not appropriate due to inadequate response or 
contraindication, and in patients undergoing major surgery, treatment with virally-
inactivated plasma-derived concentrate is recommended (30,39). Table 2 shows the 
VWF/FVIII products licensed in Europe for the treatment of VWD. Many studies 
 documented the efficacy of VWF/FVIII concentrates as prophylaxis of bleeding in 
VWD patients undergoing surgery or invasive procedures (40-48). 
     The recent literature shows that the best management of VWD undergoing 
surgery includes a pharmacokinetic study to tailor the loading and maintenance 
doses of VWF/FVIII concentrates for each patient (49). This is particularly important 
considering the heterogeneous nature of VWD and plasma derived concentrates. 
The same studies also underscore that, along with VWF levels, FVIII levels should be 
monitored daily in the postoperative period in order to prevent exposure to high 
FVIII levels, which can increase the thrombotic risk. Therefore, primary prophylaxis 
with low molecular weight heparin at the same dosages and schedules used in the 
general population, are recommended in VWD patients undergoing major surgery or 
procedures at high risk of venous thromboembolism (50). In this regard, there is a 
growing interest in replacement therapy with VWF concentrates almost devoid of 
FVIII (Wilfactin®). The same considerations are applicable for long-term secondary 
prophylaxis, particularly in patients with cardiovascular/thromboembolic risk factors. 
Recently recombinant VWF concentrate has been licensed in the USA. Safety and 
pharmacokinetics (PK) of recombinant von Willebrand factor (rVWF) combined at a 
fixed ratio with recombinant factor VIII (rFVIII) were recently reported in a 
prospective phase 1, multicenter, randomized clinical trial. rVWF was well tolerated 
and no thrombotic events, inhibitors, or serious adverse events were observed (51). 
 
Bleeding phenotype in VWD 
     Clinically, the leading symptom in VWD is bleeding, chiefly of mucosal origin. In 
the most severe forms of VWD, especially type 3, joint and muscle bleeding 
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resembling that seen in moderate haemophilia A may also be observed. Type 1 VWD 
typically manifests with mild mucocutaneous bleeding but symptoms can be more 
severe when VWF levels are lower than 15 IU/dL. Epistaxis and bruising are common 
symptoms among children, frequently and severely enough to cause anemia. 
Epistaxis also often occurs in type 2A, 2B and 2M VWD. Severe epistaxis causes 
interference or distress with daily or social activities, and impacts in QoL of patients 
(52,53). 
     Most cases of epistaxis can be managed with conservative techniques, but in 
some cases, cauterization (chemical or electrical) or nasal packing is required. In rare 
cases, surgical cauterization or sphenopalatine artery ligation or embolization is 
necessary to control severe epistaxis. 
     Type 2 A and type 3 VWD patients often experience other symptoms such 
menhorragia as and GI bleeding due to angiodysplasia or unlinked to a vascular 
lesions. Menorrhagia is the most common finding in women of reproductive age (54-
56). Objectively, menorrhagia is defined as bleeding that lasts for more than seven 
days or results in the loss of more than 80 ml of blood per menstrual cycle. 
Treatment of menorrhagia in women with inherited bleeding disorders should be 
individualized. Available treatments include hormonal therapy (oral contraceptives, 
depot medroxyprogesterone acetate, danazol, GnRH analogs) or local treatments 
(levonorgestrel-releasing Mirena coil) and non-hormonal therapy such as 
desmopressin, and tranexamic acid. For women who have completed their family 
endometrial ablation is another highly effective option. Patients are often non-
responsive to the above treatments and may require VWF/FVIII replacement therapy 
to stop or prevent the heavy bleeding. 
      Postpartum hemorrhage (PPH) remains one of the leading causes of maternal 
morbidity and mortality worldwide and is a problem for type 3 and some 2A VWD 
women where the endogenous FVIII/VWF does not normalize with pregnancy. A 
treatment algorithm for severe persistent PPH has been developed, including 
mechanical or surgical maneuvers such as intrauterine balloon tamponade or 
hemostatic brace sutures with hysterectomy as the final surgical option for 
uncontrollable PPH. Pharmacologic options include hemostatic agents such as 
tranexamic acid, with timely transfusion of blood and plasma products playing an 
important role in persistent and severe PPH (57). 
     Gastrointestinal bleeding associated with angiodysplasia, is a challenging 
complication in mostly elderly individuals where surgical treatment is often not 
feasible. Angiodysplasia is a vascular malformation and is associated with both 
inherited and acquired VWD (58-59). In inherited VWD it is seen particularly in 
patients lacking high-molecular-weight (HMW) multimers (type 2 and type 3).  In 
ĂĐƋƵŝƌĞĚst ŝƚ ŝƐŽĨƚĞŶƐĞĞŶ ŝŶ,ĂǇĚĞ ?ƐƐǇŶĚƌome associated with aortic stenosis 
where the loss of HMW multimers plays a role in the pathogenesis of the acquired 
VWD (58).  Affected patients may need to be hospitalized for long periods of time 
and often require several weeks of treatment leading to high costs and poor quality 
of life. Due to its tendency of recurrence, angiodysplasia-associated with 
gastrointestinal bleeding is an indication for secondary long-term prophylaxis (58). 
The von Willebrand Disease Prophylaxis Network (VWD PN) reported that GI 
bleeding was the most common reason for initiation of prophylaxis in adults (34%) 
(61). A number of alternative therapeutic measures have been attempted in the last 
few years in the management of recurrent gastrointestinal bleeding in VWD (62). 
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Oestrogens, progestogens and the somatostatin analogue octreotide have been 
tried, but from the little available data it is not possible to obtain solid conclusions 
on their effectiveness. More recently, interest has been focused on the use of drugs 
with angiostatic properties, such as thalidomide, but few case reports are available, 
reporting an improved clinical picture and the reduction of the transfusion 
requirement (63,64). A positive effect on refractory gastrointestinal bleeding in two 
patients with VWD has also been reported with atorvastatin, that has anti-
angiogenic properties when administered at very large doses (up to 80 mg daily) 
(65,66). 
     Finally, type 3 VWD is characterized by the most severe haemophilia-like bleeding 
phenotype (67). Particularly in this setting of patients it is logical to translate the 
success of prophylaxis in haemophilia to severe VWD. Prophylaxis can be 
implemented early in life in a home setting, and prevention of bleeding and its 
consequences is possible. 
 
Long-term prophylaxis 
     Patients with severe forms of VWD may present a severe bleeding phenotype, 
and in these patients secondary long-term prophylaxis with VWF/FVIII concentrate 
may represent the optimal therapy rather than on-demand treatment on the 
occasion of bleeding episodes. However, some differences must be considered 
between VWD and haemophilic patients regarding treatment. Firstly the differential 
pharmacokinetic behavior of VWF and FVIII, since it is known that infusion of 
VWF/FVIII concentrates in patients with severe VWD with very low levels of FVIII 
 induces an immediate rise of FVIII levels (68), followed by a secondary rise due to 
binding and stabilization of endogenous FVIII to the infused VWF. The content of 
FVIII and VWF vary widely among licensed products (30) and different profiles may 
be obtained after infusion. The second important difference is the variability of the 
bleeding phenotype among VWD patients, as well as the hemostatic response to 
concentrates, variable according to type of bleed (mucosal or joint bleeds). 
dŚĞ ĨŝƌƐƚ  “ůĂƌŐĞ ? ĞǆƉĞƌŝĞŶĐĞ ŽŶ ƚŚĞ ĞĨĨŝĐĂĐǇ ŽĨ ƐĞĐŽŶĚĂƌǇ ƉƌŽƉŚǇůĂǆŝƐ ŝŶ st ǁĂƐ
gained in Sweden in 35 patients with severe VWD (69). The investigators concluded 
that long-term prophylaxis is warranted in the majority of cases with type 3, and in 
some cases with other types of VWD resulting in a substantial decrease in the 
annual number of bleeding events. The population investigated was mostly type 3 
VWD patients, with a median age at start of prophylaxis of 13 years. The 
predominant indications for prophylaxis were nose, mouth and joint bleeds. The 
number of bleeds was significantly reduced after prophylaxis and children starting 
prophylaxis before 5 years of age never developed arthropathy.  Secondary 
prophylaxis was also retrospectively evaluated in a subgroup of a cohort of 100 
Italian VWD patients (70), 71% of whom had VWF:RCo levels <10IU/dL. Among the 
100 patients, 11 underwent 17 episodes of long-term secondary prophylaxis to 
prevent recurrent bleeding at the same site (mostly gastrointestinal and joint 
bleeding). The clinical responses were rated as excellent or good in 100% of cases, 
with a significant reduction in annual consumption of concentrate, number of 
transfused blood units and number of days spent in hospital. During the 4358 days 
of prophylaxis (median 201, range 30-730) only four bleeding episodes were 
observed. Similar results of excellent efficacy were reported in a larger cohort, with 
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32 long-term prophylaxis applied in children, adolescent and young adults with 
VWD; recurrent bleeding stopped in 31 patients, the monthly bleeding frequency 
and the bleeding score was significantly reduced compared to the pre-prophylaxis 
rate but one patient developed inhibitor (71). Each of these three studies were 
retrospective and involved a relatively small number of patients. 
     In 2008 an international study group, the VWD PN was established to study the 
role of prophylaxis in VWD; 74 centres from around the world participated. The first 
network-sponsored survey by the centres showed that the use of prophylaxis was 
rare in type 1 and 2 VWD patients but was most common in type 3 disease. 
Prophylaxis was given to prevent joint bleeding (40%), epistaxis/oral bleeding (23%), 
gastrointestinal bleeding (14%) and menorrhagia (5%) (72). 
     Between 2008 and 2011, the VWD International Prophylaxis (VIP) study was 
conducted by the network and which contained both retrospective and prospective 
components; the aims were to retrospectively evaluate the effect of prophylaxis on 
bleeding frequency and prospectively confirm the efficacy and address issues of 
cost-effectiveness and quality of life. The main conclusion of the retrospective 
analysis was the efficacy of prophylactic treatment, particularly in FVIII-dependent 
haemorrhages. Differences in annualized bleeding rates within individuals (during 
prophylaxis vs before prophylaxis) were significant for the total group (P < 0.0001), 
and for those with primary indications of epistaxis (P = 0.0005), joint bleeding (P = 
0.002) and GI bleeding (P = 0.001). The limitations of this study include the 
retrospective design and the fact that the inclusion criteria (prophylaxis for at least 6 
months and demonstrated compliance) may represent a bias by removing from 
observation patients for whom prophylactic regimen was abandoned because of 
 lack of success or acceptability. The prospective study evaluated the effect of 
prophylaxis in a treatment escalation study design (73). However, only 11 patients 
completed the protocol, and this is a major limitation of the observation. The aim of 
the study was to establish the optimal treatment regimens for the most common 
bleeding conditions in clinically severe VWD, but the statistical power of the 
population was insufficient for this evaluation. The results showed that the use of 
prophylaxis with appropriate stepwise dose escalation decreased the median 
annualized bleeding rate from 25 to 6.1 (CI of the rate difference: -51.6, -1.7) and the 
median annualized bleeding rate was even lower (4.0; CI: -57.5, -5.3) when the 
subjects reached their final dosing level. 
     With the objective of investigating the response to prophylaxis, focusing on 
specific bleeding type, a recent analysis was conducted combining data from the 
retrospective and prospective VIP study, and analyzing a cohort of 105 subjects (74). 
The authors concluded that institution of regular replacement therapy has a 
dramatic effect on bleeding frequency but does not change the proportions of type 
of bleeds that occur to a great extent.  There is variation among patients with regard 
to response to therapy, both among and within subtypes of VWD. GI bleeding stands 
out as having a lower response to prophylaxis than other bleeding sites and 
requiring more frequent prophylactic infusions.  It was also noted that when the 
treatment frequency is escalated for joint bleeding, higher doses were used. 
    Table 3 shows the studies reporting on the use of long-term prophylaxis in VWD. 
Although clinical experience with VWD/FVIII prophylaxis has been rated as 
satisfactory, some uncertainties persist such as the optimal dose of concentrate and 
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the regimen for prophylaxis, due to the wide heterogeneity of the bleeding tendency 
that impacts heavily on QoL. 
     
CONCLUSION/FUTURE Perspectives 
A selected population of VWF with severe bleeding phenotype may benefit from 
long-term prophylaxis with VWF concentrate.  The standardization and validation of 
ƚŚĞ ůĞĞĚŝŶŐ ^ĐŽƌĞ  ? ? ? ? ? ĂŶĚ ŝƚƐ ĂƉƉůŝĐĂƚŝŽŶ ƚŽ ĞǀĂůƵĂƚĞ ƚŚĞ ƉĂƚŝĞŶƚƐ ? ƚĞŶĚĞŶĐǇ ƚŽ
bleed (76-78) will likely aid individualizing therapy. 
     In contrast to haemophilia, pharmacoeconomic analysis to assess the economic 
impact of treatment of severe VWD, comparing on demand versus prophylactic 
regimens are still lacking. A recent Italian cost-analysis on long-term prophylaxis in 
VWD in the Italian context (79) showed (with some limitations due to the single case 
reports used for the analysis) that long-term prophylaxis with VWF with a low FVIII 
content is likely to be a cost-effective approach with a favorable impact on the 
reduction of health care resource consumption and with the improvement in the 
QoL of the patients.  However, more prospective trials are needed to evaluate the 
cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐĂŶĚƚŚĞŝŵƉƌŽǀĞŵĞŶƚŽŶĂƉĂƚŝĞŶƚ ?ƐYŽ>ŽĨůŽŶŐ-term prophylaxis. 
VWF produced by recombinant technology could offer an additional option for the 
treatment of VWD by eliminating infective risks associated with plasma products. It 
is now time to seriously consider prophylaxis for severe VWD as a standard of care 
rather than novelty. 
  
Table 1 
Evidence-based recommendations for surgery prophylaxis in von Willebrand disease. 
Autologous replacement therapy (DDAVP) 
 
Surgical or invasive procedures should be covered with DDAVP in responsive 
patients unless contraindicated 
A DDAVP test infusion measuring FVIII:C and VWF:RCo levels at 1 hour (peak) 
and 4 hour (clearance) is recommended before the clinical use of the drug, 
owing to within-patients consistency in response 
In type 1 with baseline VWF:RCo and FVIII:C levels >10U/dL, DDAVP is usually 
an effective treatment 
In type 2A, DDAVP may be used if a test infusion indicates an adequate 
response 
In Type 2B, DDAVP is contraindicated 
In Type 2M, DDAVP may be used if a test infusion indicates response 
In Type 2N, DDAVP may be effective but the half-life of FVIII is shortened 
In Type 3, DDAVP is ineffective 
Allogenic replacement therapy (VWF/FVIII or VWF concentrates) 
 
Patients unresponsive to DDAVP or in whom DDAVP is contraindicated, should 
be treated with virus-inactivated plasma-derived VWF/FVIII concentrates 
Prophylaxis for major surgery: daily doses of 50 IU/kg of VWF/FVIII to maintain 
FVIII:C level >50 U/dL until healing is complete (usually 5-10 days)* 
Prophylaxis for minor surgery: daily or every other day doses of 30-60 IU/Kg of 
VWF/FVIII to maintain FVIII:C level >30 U/dL until healing is complete (usually 
2-4 days)* 
Prophylaxis for dental extractions or invasive procedures: single dose of 30 
IU/Kg of VWF/FVIII to maintain FVIII:C level >50 U/dL for 12 hours* 
Measure plasma levels of FVIII:C and VWF:RCo every 12 hours on the day of 
surgery, then every 24 hours 
A dosing pharmacokinetic study should be considered before major surgery, 
particularly for type 3 VWD patients 
*these dosages are indicated for VWD patients with severely reduced FVIII:C/VWF:RCo levels 
 (less than 10 U/dL). 
 
Adapted from Mannucci et al, Blood Transfus 2009; 7: 117-126 
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Table 2. 
VWF/FVIII products licensed for the treatment of von Willebrand disease. 
Product Manufacturer Purification Viral inactivation VWF:RCo/Ag  
(ratio) 
VWF:RCo/FVIII  
(ratio) 
Alphanate Grifols Heparin ligand 
chromatography 
S/D + dry heat 
(80°C, 72h) 
0.47 + 0.1 0.91 + 0.2 
Factor 8Y BioProducts 
Laboratory 
Heparin/glycine 
precipitation 
Dry heat 
(80°C,72h) 
0.29 0.81 
Fandhi Grifols Heparin ligand 
chromatography 
S/D + dry heat 
(80°C, 72h) 
0.47 + 0.1 1.04 + 0.1 
Haemate P CSL Behring Multiple 
precipitation 
Pasteurization 
(60°C, 10h) 
0.59 + 0.1 2.45 + 0.3 
Immunate Baxter Ion exchange 
chromatography 
S/D + vapor heat 
(60°C, 10 h) 
0.47 1.1 
Wilate Octapharma Ion exchange + 
size exclusion 
chromatography 
S/D + dry heat 
(100°C, 72h) 
- 0.9 
Wilfactin LFB Ion exchange + 
affinity 
S/D, 35 nm 
filtration, dry heat 
(80°C, 72 h) 
ࢉ  0.95 ࢉ  50 
Vocento CSL Behring Multiple 
precipitation + 
albumin ligand 
chromatography 
S/D + Dry heat - 2.4 
 
 
VWF: von Willebrand factor; RCo: ristocetin co-factor; Ag: antigen; FVIII: factor VIII; S/D: solvent/detergent; 
D: detergent  ;  ࢉ : approximately 
Adapted from Castaman G, Haematologica 2013; 98: 667-674. 
 
 
 
 
 Table 3 
Studies reporting on the use of long-term prophylaxis in VWD 
 
 
Author, year 
Design, 
Reference 
citation 
 
Patients 
Median age at 
start of 
prophylaxis 
Median 
time on 
prophylaxis 
 
 
Type of 
VWD 
 
 
 
Primary bleeding 
indication 
 
Main results 
 
 
Berntorp, 2005 
Retrospective 
 
 
37 
 
 
13 (1-61) 
 
 
11 years 
(2-45) 
 
Type 3: 28 
Type 2: 6 
Type 1: 3 
 
Mucocutaneous 
bleeds and joint 
bleeds 
Number of bleeds 
reduced after 
prophylaxis. No 
arthropathy in children 
starting prophylaxis 
before 5 years of age. 
 
 
 
Federici AB, 2007 
Retrospective 
 
 
 
11 
 
 
 
- 
 
 
 
- 
 
 
Type 3: 5 
Type 2A: 4 
Type 2M: 1 
Type 1: 1 
 
 
 
GI bleeding: 7 
Joint bleeding: 4 
Clinical responses 
excellent or good in 
100% of cases. 
Significant reduction of 
annual consumption of 
concentrates, n. of 
transfused blood units 
and n. of days spent in 
hospital. 
Halimeh S, 2011 
Retrospective 
32 Children: 13 
Adolescents: 7 
Adults: 12 
3 years Type 1: 4 
Type 2: 15 
Type 3: 13 
- Recurrent bleeding 
stopped in 31 patients. 
Monthly bleeding 
frequency  significantly 
reduced (p<0.001) 
 
Abshire T, 2013 
Retrospective 
 
59 
 
22,4 (2.3-7.2) 
 
2.2 years 
Type 3: 34 
Type 2A: 10 
Type 2B: 8 
Type 2M: 2 
Type 1: 5 
 
GI bleeding: 13 
Epistaxis: 13 
Joint bleeding: 12 
Significant reduction in 
median within-
individual n. of 
bleeds/year (p<0,0001) 
 
 
Abshire T, 2015 
Prospective 
 
 
11 
 
 
34.6 (3-80.6) 
 
 
- 
Type 3: 54 
Type 2A: 25 
Type 2B: 9 
Type 2M: 3 
Type 2 unk: 
1 
Type 1: 13 
 
Epistaxis: 6 
GI bleeding: 3 
Joint bleeding: 2 
Median annualized 
bleeding score from 35 
to 6.1 (95% C.I.:51.6 to 
1.7) 
 
 
Holm E, 2015 
Prospective and 
retrospective 
(74)
 
 
 
95 retr. 
11 prosp. 
 
 
Mean: 26 (1-
81) 
 
 
- 
 
 
- 
Adults: 
GI bleeding 34% 
Joint bleeding 
20.8% 
Children: 
Epistaxis 43.2% 
Joint bleeding 
31.8% 
Significant median 
reduction in bleeding, 
within individuals, for 
epistaxis (p<0,0001), 
GI bleeding (p<0,0003), 
joint bleeding 
(p<0,0001) and 
menorrhagia (p=0.008) 
Miesbach W,  
2015 
(80)
 
Retrospective 
3 - - Type 3: 2 
Type 2A: 1 
GI bleeding Resolution of GI 
bleeding in 2 of the 3 
patients 
19 
 
Khair K, 2015 
(81)
 
Retrospective 
4 Mean age: 6.8 - Type 3: 4 GI bleeding: 1 
Joint bleeding: 3 
No bleeding during 
prophylaxis 
Batty P, 2014 
(82)
 
Retrospective 
8 Home 
treatment: 
4 regular 
prophilaxis 
2 on demand 
1 targeted 
prophilaxis 
1 
intermittent 
prophilaxiso
n demand 
 
 
Adults >18 
years 
- - - Efficacy rated as 
excellent or good in 96% 
cases. No treatment 
failure. 
Nowal-Gottl U, 
2013 
(83)
 
Prospective 
15 tot 
(prophilaxis 
on demand, 
surgical 
procedures) 
Children<6 
years 
- - - Efficacy rated as 
excellent or good in 
99.7% cases. 
No inhibitors 
development. No 
thromboembolic events. 
Castaman G, 
2013 
(84)
 
Prospective 
31 patients- 
secondary 
long term 
prophylaxis 
- - Type 1: 9 
Type 2A: 1 
Type 2B: 5 
Type 3: 16 
Joint bleeding (41 
events) 
GI bleeding (34 
events) 
Menorrhagia (17 
events) 
Good to excellent 
response in 92.9% 
cases; 
Moderate and poor in 
6.3 % cases 
Howman R, 2011 
(85)
 
Retrospective 
2 - - Type 3: 2 - Prevention of bleeding 
in 1 patient. 
Poor response and 
inhibitor development 
in 1 patients. 
 
*  Not a primary study  W it includes patients from other studies on this table 
Prophy=prophylaxis 
n.=number 
retr.=retrospective 
prosp.=prospective 
tot.=total 
on dem. = on demand 
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